Sutherland Kate, Takaya Hisashi, Qian Jin, Petocz Peter, Ng Andrew T, Cistulli Peter A
Centre for Sleep Health and Research, Department of Respiratory Medicine, Royal North Shore Hospital, Sydney Medical School, University of Sydney, Australia.
Woolcock Institute of Medical Research, University of Sydney, Australia.
J Clin Sleep Med. 2015 Aug 15;11(8):861-8. doi: 10.5664/jcsm.4934.
Mandibular advancement splints (MAS) are an effective treatment for obstructive sleep apnea (OSA); however, therapeutic response is variable. Younger age, female gender, less obesity, and milder and supine-dependent OSA have variably been associated with treatment success in relatively small samples. Our objective was to utilize a large cohort of MAS treated patients (1) to compare efficacy across patients with different phenotypes of OSA and (2) to assess demographic, anthropometric, and polysomnography variables as treatment response predictors.
Retrospective analysis of MAS-treated patients participating in clinical trials in sleep centers in Sydney, Australia between years 2000-2013. All studies used equivalent customized two-piece MAS devices and treatment protocols. Treatment response was defined as (1) apnea-hypopnea index (AHI) < 5/h, (2) AHI < 10/h and ≥ 50% reduction, and (3) ≥ 50% AHI reduction.
A total of 425 patients (109 female) were included (age 51.2 ± 10.9 years, BMI 29.2 ± 5.0 kg/m2). MAS reduced AHI by 50.3% ± 50.7% across the group. Supine-predominant OSA patients had lower treatment response rates than non-positional OSA (e.g., 36% vs. 59% for AHI < 10/h). REM-predominant OSA showed a lower response rate than either NREM or non-stage dependent OSA. In prediction modelling, age, baseline AHI, and anthropometric variables were predictive of MAS treatment outcome but not OSA phenotype. Gender was not associated with treatment outcome.
Lower MAS treatment response rates were observed in supine and REM sleep. In a large sample, we confirm that demographic, anthropometric, and polysomnographic data only weakly inform about MAS efficacy, supporting the need for alternative objective prediction methods to reliably select patients for MAS treatment.
下颌前移矫治器(MAS)是治疗阻塞性睡眠呼吸暂停(OSA)的一种有效方法;然而,治疗反应存在差异。在相对较小的样本中,较年轻的年龄、女性、较少的肥胖以及较轻且依赖仰卧位的OSA与治疗成功存在不同程度的关联。我们的目的是利用一大群接受MAS治疗的患者,(1)比较不同OSA表型患者的疗效,(2)评估人口统计学、人体测量学和多导睡眠图变量作为治疗反应预测指标。
对2000年至2013年间在澳大利亚悉尼睡眠中心参与临床试验的接受MAS治疗的患者进行回顾性分析。所有研究均使用等效的定制两件式MAS装置和治疗方案。治疗反应定义为:(1)呼吸暂停低通气指数(AHI)<5次/小时,(2)AHI<10次/小时且降低≥50%,(3)AHI降低≥50%。
共纳入425例患者(109例女性)(年龄51.2±10.9岁,体重指数29.2±5.0kg/m²)。全组患者MAS使AHI降低了50.3%±50.7%。以仰卧位为主的OSA患者的治疗反应率低于非体位性OSA患者(例如,AHI<10次/小时时分别为36%和59%)。以快速眼动(REM)睡眠为主的OSA患者的反应率低于非快速眼动(NREM)睡眠或非分期依赖性OSA患者。在预测模型中,年龄、基线AHI和人体测量学变量可预测MAS治疗结果,但OSA表型不能。性别与治疗结果无关。
在仰卧位和REM睡眠中观察到较低的MAS治疗反应率。在一个大样本中,我们证实人口统计学、人体测量学和多导睡眠图数据对MAS疗效的预测作用较弱,这支持了需要替代的客观预测方法来可靠地选择接受MAS治疗的患者。